Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
Elisabetta Munzone, Eleonora Pagan, Vincenzo Bagnardi, et al.
ESMO Open (2021) Vol. 6, Iss. 6, pp. 100332-100332
Open Access | Times Cited: 25

Showing 25 citing articles:

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2015-2015
Open Access | Times Cited: 23
Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review
Dongqing Pu, Debo Xu, Yue Wu, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 1
Open Access | Times Cited: 7
The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
Dongqing Pu, Yue Wu, Debo Xu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Elisabetta Munzone, Meredith M. Regan, Saverio Cinieri, et al.
JAMA Oncology (2023) Vol. 9, Iss. 9, pp. 1267-1267
Open Access | Times Cited: 16
A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer
Hanqiao Shao, Mingye Zhao, Ai‐Jia Guan, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer
Antonella Ferro, Michela Campora, A. Caldara, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 12, pp. 3611-3611
Open Access | Times Cited: 5
Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer
Paola Ferrari, Maria B. Schiavone, Cristian Scatena, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3438-3438
Open Access
Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)
M. Teomete, Devrim Çabuk, Taner Korkmaz, et al.
Oncology Letters (2024) Vol. 27, Iss. 4
Open Access | Times Cited: 3
Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review
Melody Zhao, Kent A. Hanson, Yixie Zhang, et al.
Targeted Oncology (2023) Vol. 18, Iss. 3, pp. 327-358
Open Access | Times Cited: 8
FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway
Guanglei Chen, Lisha Sun, Xi Gu, et al.
Science China Life Sciences (2023) Vol. 66, Iss. 12, pp. 2805-2817
Closed Access | Times Cited: 7
Real‐world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database
Hope S. Rugo, Xianchen Liu, Benjamin Li, et al.
International Journal of Cancer (2023) Vol. 154, Iss. 4, pp. 701-711
Open Access | Times Cited: 7
How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
Viola Cogliati, Serena Capici, Francesca Pepe, et al.
Life (2022) Vol. 12, Iss. 3, pp. 378-378
Open Access | Times Cited: 12
Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i
Véronique Barrès, S. P. Kane, Belal Howidi, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?
Martina Perrone, Francesco Giuliani, Valeria Sanna, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 8, pp. 887-900
Closed Access | Times Cited: 4
Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
Federica Villa, Alessandra Crippa, Davide Pelizzoni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14427-14427
Open Access | Times Cited: 4
Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer
Nicholas J. Robert, Connie Chen, Sindy Kim, et al.
Future Oncology (2024) Vol. 20, Iss. 12, pp. 761-780
Open Access | Times Cited: 1
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial
Ilenia Migliaccio, Dario Romagnoli, Francesca Galardi, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 1
A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: a review of current and investigational treatment for HR+/Her2- breast cancer
Serena Astore, Ester Oneda, Alberto Zaniboni
Critical Reviews in Oncology/Hematology (2024), pp. 104535-104535
Closed Access | Times Cited: 1
Utidelone combined with anti‑angiogenic therapy for the treatment of anthracycline/taxane‑treated and endocrine‑resistant HR+/HER2‑ refractory breast cancer with brain metastases: A case report
Xue Bai, Meidi Liu, Xuelian Chen, et al.
Oncology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Prognostic value of [18F]-FDG PET/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors
Alessio Annovazzi, Sandra Rea, Daria Maccora, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis
Marcin Kubeczko, Anna Polakiewicz-Gilowska, K Swiderska, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study
Zhe-Yu Hu, Binliang Liu, Ning Xie, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer
Lis Victória Ravani, Pedro Calomeni, Maysa Vilbert, et al.
JCO Oncology Practice (2024)
Closed Access
Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction
Lizhi Ning, Yaobang Liu, Xuefang He, et al.
American Journal of Clinical Oncology (2023)
Closed Access | Times Cited: 1
Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2– metastatic breast cancer: a prospective, monocentric study
Raffaella Palumbo, Erica Quaquarini, Giuseppe Saltalamacchia, et al.
Drugs in Context (2023) Vol. 13, pp. 1-11
Open Access
Page 1

Scroll to top